title: Trachea, lung, and tracheobronchial lymph nodes are the major sites where antigen-presenting cells are detected after nasal vaccination of mice with human papillomavirus type 16 virus-like particles.
abstract: Vaccination by the nasal route has been successfully used for the induction of immune responses. Either the nasal-associated lymphoid tissue (NALT), the bronchus-associated lymphoid tissue, or lung dendritic cells have been mainly involved. Following nasal vaccination of mice with human papillomavirus type 16 (HPV16) virus-like-particles (VLPs), we have previously shown that interaction of the antigen with the lower respiratory tract was necessary to induce high titers of neutralizing antibodies in genital secretions. However, following a parenteral priming, nasal vaccination with HPV16 VLPs did not require interaction with the lung to induce a mucosal immune response. To evaluate the contribution of the upper and lower respiratory tissues and associated lymph nodes (LN) in the induction of humoral responses against HPV16 VLPs after nasal vaccination, we localized the immune inductive sites and identified the antigen-presenting cells involved using a specific CD4(+) T-cell hybridoma. Our results show that the trachea, the lung, and the tracheobronchial LN were the major sites responsible for the induction of the immune response against HPV16 VLP, while the NALT only played a minor role. Altogether, our data suggest that vaccination strategies aiming to induce efficient immune responses against HPV16 VLP in the female genital tract should target the lower respiratory tract.
authors.affiliation: Department of Gynecology, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland.
authors.forename: Carole
authors.initials: C
authors.lastname: Balmelli
authors.forename: Stéphane
authors.initials: S
authors.lastname: Demotz
authors.forename: Hans
authors.initials: H
authors.lastname: Acha-Orbea
authors.forename: Pierre
authors.initials: P
authors.lastname: De Grandi
authors.forename: Denise
authors.initials: D
authors.lastname: Nardelli-Haefliger
mesh_terms: D000281:Administration, Intranasal; D000818:Animals; D000938:Antigen-Presenting Cells / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology / Q000821:virology; D001980:Bronchi / Q000276:immunology*; D036022:Capsid Proteins; D003001:Cloning, Molecular; D003713:Dendritic Cells / Q000276:immunology / Q000821:virology; D005260:Female; D006825:Hybridomas / Q000276:immunology; D008168:Lung / Q000276:immunology*; D008198:Lymph Nodes / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D009856:Oncogene Proteins, Viral / Q000276:immunology*; D027383:Papillomaviridae / Q000276:immunology*; D014132:Trachea / Q000276:immunology*; D014611:Vaccination; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*; D014771:Virion / Q000276:immunology*
chemical_list: D036022:Capsid Proteins; D009856:Oncogene Proteins, Viral; D014765:Viral Vaccines; C063317:L1 protein, Human papillomavirus type 16